Navigation Links
Ziehm Imaging Extends its Training Offer
Date:10/13/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015  Kerastem Technologies announce that the ... U.S. FDA Center For Biologics Evaluation and Research (CBER) ... a clinical trial investigating the safety and feasibility of ... early male pattern baldness (androgenic alopecia). The ... initial clinical work in Europe ...
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 ... of health care services and one of the ... announced that its parent company and sole stockholder, ... with Medical Properties Trust, Inc. ("MPT") (NYSE: ... million in cash.  The transaction is expected to be ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... Calif., Oct. 27 Nektar,Therapeutics (Nasdaq: NKTR ) ... and analysts at the InterContinental Hotel in New York ... Time. The,webcast portion of this event will conclude at ... of a series of presentations and Q&A,related to the ...
... in Improvements in Physical ... and Health-Related Quality of Life, SAN FRANCISCO, Oct. ... week subcutaneous injections of golimumab (CNTO 148),50 mg and ... joint and skin symptoms of active psoriatic arthritis,through six ...
... Inc.,(Nasdaq: TRBN ) today announced positive ... repeat administration with TRU-015 continues to produce,persistent ... signs and symptoms based on American College ... results following preliminary,analyses from a Phase 2b ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... development at the University of Nevada School of Medicine for ... human trials with a $308,000 boost from the Muscular Dystrophy ... research by Associate Professor of Pharmacology Dean Burkin that has ... devastating neuromuscular disease in mouse models. "The early ...
... 30 minutes of daily training provide an equally effective loss of ... been published in the American Journal of Physiology . ... a research team at the Faculty of Medical and Health Sciences ... efforts to get into better shape. Half of the men were ...
... director of Fred Hutchinson Cancer Research Center, has ... internationally renowned expert in virology, immunology and vaccine ... and other viral infections, particularly those associated with ... the safety of daily antiviral treatment for immunocompetent ...
Cached Biology News:MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 2MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 330 minutes of daily exercise does the trick 2The American Society for Microbiology honors Lawrence Corey 2The American Society for Microbiology honors Lawrence Corey 3
... specifically formulated for mounting tissue specimens, cell ... with immunohistochemical methods for viewing by light ... chromogens, such as AEC, that are alcohol-soluble ... completely when slides are cover-slipped forming a ...
... Vision Mount is formulated for covering tissue sections and cell ... insoluble end products. , ... Application: ... Fast-Red or AEC that require an aqueous mounting medium, or ...
... to JNK1 (phospho T183 + Y185) Immunogen ... containing phosphorylated T183/Y185. Reactivity / Specificity ... tested in other species. Background Information ... ERK, JNK, and p38 kinases. The members are ...
... Target Retrieval Solution, High pH, Concentrated x ... intended for heat-induced target retrievel prior to ... on formalin-fixed, paraffin-embedded tissue sections mounted on ... at high pH, 9.9, is especially effective. ...
Biology Products: